Janus Henderson Group PLC Cassava Sciences Inc Transaction History

Janus Henderson Group PLC

  • $187 Billion
  • Q3 2024

A detailed history of Janus Henderson Group PLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Janus Henderson Group PLC holds 16,436 shares of SAVA stock, worth $435,225. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,436
Previous 16,436 -0.0%
Holding current value
$435,225
Previous $202,000 139.11%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$12.35 - $26.11 $2,531 - $5,352
-205 Reduced 1.23%
16,436 $202,000
Q1 2024

May 15, 2024
BUY
$18.44 - $26.41 $18 - $26
1 Added 0.01%
16,641 $337,000
Q4 2023

Feb 14, 2024
SELL
$12.64 - $30.11 $391 - $933
-31 Reduced 0.19%
16,640 $374,000
Q3 2023

Nov 14, 2023
BUY
$16.64 - $25.32 $149 - $227
9 Added 0.05%
16,671 $277,000
Q2 2023

Aug 14, 2023
SELL
$21.59 - $27.88 $604 - $780
-28 Reduced 0.17%
16,662 $408,000
Q1 2023

May 15, 2023
BUY
$23.46 - $36.44 $214,799 - $333,644
9,156 Added 121.53%
16,690 $402,000
Q4 2022

Feb 14, 2023
BUY
$27.82 - $44.16 $209,595 - $332,701
7,534 New
7,534 $222,000
Q3 2022

Nov 14, 2022
BUY
$16.33 - $51.06 $16 - $51
1 Added 0.01%
7,534 $315,000
Q2 2022

Aug 15, 2022
BUY
$17.22 - $38.47 $17 - $38
1 Added 0.01%
7,533 $212,000
Q1 2022

May 16, 2022
BUY
$32.6 - $53.05 $245,543 - $399,572
7,532 New
7,532 $280,000

Others Institutions Holding SAVA

# of Institutions
207
Shares Held
14M
Call Options Held
2.98M
Put Options Held
6.57M
View Full List

About CASSAVA SCIENCES INC

SAVA Quotes by TradingView
  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.06B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email